IL6 and type 2 diabetes mellitus: A cross-over randomized controlled trial with a duration of 8 weeks and a wash-out period of 4 weeks in 31 overweight T2DM patients found significant reductions concerning CRP, interleukine-6 (IL-6), and tumor necrosis factor-a (TNF-a).